October 29, 2024 – Talk Bio

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

6 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing

6 months ago talkbio0Tagged delayed approval, MorphoSys, Novartis, Safety, Signal

Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals

GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager

6 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Chimagen, Lupus Vulgaris, pharmaceutical deals, SmithKline Beecham, T-Lymphocyte

GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals

Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration

6 months ago talkbio0Tagged Administration occupational activities, Agriculture, Biopharma, Health care facility, Policy, RFK Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy

WuXi AppTec Continues to Attract New Clients Amid BIOSECURE Act Uncertainty

6 months ago talkbio0Tagged AppTec, BIOSECURE, chain vulnerabilities, Chinese, Chinese contract manufacturer, Clients, Drug Industry, Senate consideration, WuXi

WuXi AppTec, BIOSECURE Act, new clients, revenue decline, Chinese contract manufacturer, U.S. Senate consideration, pharmaceutical industry, supply chain vulnerabilities.

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

6 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management

6 months ago talkbio0Tagged abuse-deterrent, Approved, Opioids, Pain management, Protega Pharmaceuticals, Roxybond, SentryBond technology, United States Food and Drug Administration

FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

6 months ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns